<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2168279947"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatic sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease (VOD), is a systemic endothelial disease that typically presents in the days or weeks after hematopoietic cell transplantation (HCT) with refractory thrombocytopenia, hepatomegaly, ascites, and jaundice, and it can rapidly progress to multiorgan dysfunction and death. Rarely, SOS can arise after other causes of liver injury. A high index of suspicion is needed to diagnose hepatic SOS, and effective management is critical for reducing the associated morbidity and mortality.</p><p>The incidence, risk factors, clinical presentation, evaluation, and diagnosis of hepatic SOS differ between adults and children. This topic discusses SOS in adults.</p><p>Hepatic SOS in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/129810.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in children"</a>.)</p><p class="headingAnchor" id="H2449335631"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hepatic SOS, which is also called veno-occlusive disease (VOD), develops in up to 15 percent of adults after hematopoietic cell transplantation (HCT). The incidence of SOS varies with the patient population, aspects of transplantation, prior treatments, and predisposing risk factors. The reported incidence also differs because of evolving diagnostic criteria and variable levels of recognition and documentation [<a href="#rid1">1</a>]. </p><p>The mean incidence of hepatic SOS was 14 percent (3425 cases among nearly 25,000 transplants in adults and children) in a review that analyzed 135 studies from 1979 to 2007 [<a href="#rid1">1</a>]. Rates differed between studies, in part, because of various diagnostic criteria, but few studies reported incidence &gt;40 percent. </p><p>The incidence of SOS in adults appears to be relatively stable over recent decades [<a href="#rid1">1-6</a>]. This may reflect offsetting effects of lower-risk conditioning regimens and improved graft-versus-host disease management versus more transplants in older or heavily pretreated patients, who are more likely to have pre-existent liver injury. </p><p>Risk factors for hepatic SOS are discussed below. (See <a class="local">'Risk factors'</a> below.)</p><p class="headingAnchor" id="H765648287"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for hepatic SOS after hematopoietic cell transplantation (HCT) include pretransplant patient characteristics (eg, prior liver disease) and transplantation-related factors (eg, conditioning regimen, graft source, graft-versus-host disease [GVHD] prophylaxis regimen) (<a class="graphic graphic_table graphicRef91604" href="/d/graphic/91604.html" rel="external">table 1</a>). The odds ratios for various risk factors differ between studies [<a href="#rid2">2,7,8</a>].</p><p class="headingAnchor" id="H2571760121"><span class="h2">Patient characteristics</span><span class="headingEndMark"> — </span>The risk for hepatic SOS is increased in patients with pre-existent liver or lung disease, impaired performance status, and certain underlying diseases [<a href="#rid6">6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – Patients with pre-existent liver disease are at substantially increased risk for hepatic SOS [<a href="#rid2">2,6,7,9-14</a>]. In the largest series, the risk of developing SOS was 3 to 10 times greater in patients with increased serum aspartate aminotransferase (AST) prior to transplantation [<a href="#rid7">7</a>]. Patients with cirrhosis are at great risk for developing SOS, and most are considered ineligible for myeloablative HCT. (See  <a class="medical medical_review" href="/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1">It is unclear if the increased risk for SOS is linked to specific causes of liver disease. Patients who are seropositive for hepatitis B surface antigen and only mild or no elevations in liver enzymes are at increased risk for reactivation of the virus and GVHD but may not have an increased risk of SOS [<a href="#rid15">15</a>]. The risk in association with hepatitis C has been inconsistent [<a href="#rid16">16-20</a>]; it is unclear if effective antiviral treatment reduces that risk. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung disease</strong> – Reduced diffusion capacity (eg, &lt;70 percent of predicted) was an independent risk factor for severe SOS in a study of 307 patients who underwent HCT; this may reflect pre-existing systemic endothelial cell damage and greater susceptibility to liver injury from chemotherapy [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other pretransplant characteristics that are associated with risk for SOS are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased age [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Performance status – Poor baseline performance status or declining health status [<a href="#rid2">2,4,5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Underlying disease – Leukemias, including chronic myeloid leukemia [<a href="#rid6">6,22,23</a>].</p><p></p><p class="headingAnchor" id="H3298168562"><span class="h2">Aspects of transplantation</span><span class="headingEndMark"> — </span>Transplantation-related factors that have been associated with increased risk for hepatic SOS include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparative regimen</strong> – Myeloablative conditioning with certain alkylating agents (eg, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>) is associated with a two- to eightfold increased risk for SOS [<a href="#rid7">7,10,24-35</a>]. Radiation therapy ≥12 gray (Gy) is associated with an increased risk of hepatic SOS, especially when administered in a single dose rather than using fractionated dosing [<a href="#rid11">11,36-38</a>]. (See  <a class="medical medical_review" href="/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Hepatic vascular injury'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft source</strong> – The risk of SOS is generally higher with allogeneic grafts than autologous grafts, but this may be primarily related to the degree of alloreactivity (ie, higher risk with an unrelated donor, HLA-mismatched donor, or non-T cell depleted graft) [<a href="#rid1">1,2,39,40</a>]. It is presently unclear if there is increased risk associated with HLA-haploidentical donors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GVHD prophylaxis</strong> – Certain GVHD prophylaxis regimens, including use of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> in patients receiving <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>/total body irradiation and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> used with busulfan- or high dose etoposide-containing conditioning regimens, are associated with increased risk for SOS [<a href="#rid22">22,41-43</a>].</p><p></p><p class="headingAnchor" id="H630899066"><span class="h2">Other causes of SOS</span><span class="headingEndMark"> — </span>Recent treatment with monoclonal antibodies conjugated with calicheamicin (eg, <a class="drug drug_general" data-topicid="8968" href="/d/drug information/8968.html" rel="external">gemtuzumab ozogamicin</a>, <a class="drug drug_general" data-topicid="114511" href="/d/drug information/114511.html" rel="external">inotuzumab ozogamicin</a>) are associated with a substantially increased risk (up to 20-fold) in patients who subsequently undergo HCT [<a href="#rid44">44-47</a>]. </p><p>Other nontransplant-associated causes include chemotherapy (eg, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>) [<a href="#rid29">29</a>], ingestion of pyrrolizidine alkaloids from herbal sources (eg, bush tea) [<a href="#rid48">48</a>], high dose radiation to the liver (usually &gt;30 Gy) [<a href="#rid49">49,50</a>], radioembolization of liver tumors [<a href="#rid51">51</a>], and liver transplantation [<a href="#rid52">52,53</a>]. (See  <a class="medical medical_review" href="/d/html/3618.html" rel="external">"Hepatotoxicity due to herbal medications and dietary supplements"</a>.)</p><p class="headingAnchor" id="H3043698824"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Hepatic SOS is initiated by injury to sinusoidal endothelial cells, which is amplified by a local inflammatory response and activation of coagulation and fibrinolytic pathways, causing liver necrosis in severe disease.</p><p>The cellular injury is thought to be initiated by toxic metabolites generated by alkylating agents in conditioning regimens, ionizing radiation, or hepatotoxins [<a href="#rid4">4,54</a>]. These products damage sinusoidal endothelial cells and hepatocytes in the hepatic acinus, which creates gaps in the sinusoidal barrier through which cells and cellular debris pass into the space of Disse beneath the endothelial cells. The narrowed venous lumen reduces sinusoidal venous outflow, causes post-sinusoidal portal hypertension, and leads to widespread zonal liver disruption and centrilobular hemorrhagic necrosis. The process is compounded by cell damage from locally-released cytokines and activation of the coagulation and fibrinolytic pathways. Patients with pre-existing liver disease may have impaired drug metabolism and abnormal expression of adhesion molecules and procoagulant factors prior to hematopoietic cell transplantation (HCT) [<a href="#rid55">55-57</a>].</p><p>The pathophysiology of hepatic SOS shares features with other transplant-related, systemic endothelial diseases (eg, acute graft-versus-host disease, transplant-associated microangiopathy) and drug-associated endothelial cell injury. (See  <a class="medical medical_review" href="/d/html/3545.html" rel="external">"Pathogenesis of graft-versus-host disease (GVHD)", section on 'Acute GVHD'</a> and  <a class="medical medical_review" href="/d/html/1353.html" rel="external">"Cancer-associated hypercoagulable state: Causes and mechanisms", section on 'Therapy-related factors'</a>.)</p><p class="headingAnchor" id="H83737143"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>In adults, the peak incidence of presentation with hepatic SOS is 12 days after hematopoietic cell transplantation (HCT); although most adults present within 21 days, up to 40 percent of adults may present &gt;21 days after transplantation [<a href="#rid58">58</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – Most patients present with weight gain (≥5 percent) and edema, beginning three to six days after transplantation, followed by firm, painful hepatomegaly with ascites and jaundice [<a href="#rid7">7</a>]. Dyspnea, tachypnea, or other evidence of fluid overload may accompany renal, cardiac, or pulmonary dysfunction in patients with multiorgan dysfunction/failure; some patients with severe SOS also develop encephalopathy or other central nervous system abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> – Thrombocytopenia that is refractory to platelet transfusions is usually the earliest laboratory abnormality and it may precede clinical findings [<a href="#rid7">7,59</a>]. Most adults have elevated serum aminotransferases and/or alkaline phosphatase, while hyperbilirubinemia (mostly conjugated bilirubin) develops later; in severe disease, increased prothrombin time and other measures of impaired hepatic synthetic function may be present. Kidney function tests are abnormal in approximately half of adults.</p><p></p><p class="headingAnchor" id="H1510490258"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Evaluation of suspected SOS is primarily based on clinical and laboratory findings. Abdominal ultrasound (US) and liver biopsy are important, but not essential, aspects of evaluation and diagnosis. </p><p class="headingAnchor" id="H2197426290"><span class="h2">Clinical evaluation</span><span class="headingEndMark"> — </span>Every patient who undergoes hematopoietic cell transplantation (HCT) should be evaluated daily with an eye toward features that might suggest development of hepatic SOS. Daily evaluation should include: </p><p class="bulletIndent1"><span class="glyph">●</span>Fluid intake/output and weight.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interval history – The patient should be asked about abdominal swelling or pain, nausea/vomiting, dyspnea, peripheral edema, headache.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination for peripheral edema and other evidence of fluid accumulation, hepatomegaly, abdominal tenderness and increased girth, bleeding/bruising, and other evidence for organ dysfunction.</p><p></p><p class="headingAnchor" id="H775759227"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Laboratory studies should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Daily complete blood count (CBC) and differential count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Daily serum chemistries, including electrolytes, renal function tests, and liver function tests (eg, aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transpeptidase [GGT], total and direct bilirubin, albumin, lactate dehydrogenase [LDH]). Amylase and lipase should be measured, as clinically warranted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT); fibrinogen and other tests of coagulation, as clinically indicated.</p><p></p><p class="headingAnchor" id="H574951355"><span class="h2">Abdominal ultrasound</span><span class="headingEndMark"> — </span>Abdominal US is useful for characterizing hepatomegaly, ascites, and/or reversal of portal venous flow, which can be used to evaluate, diagnose, grade severity, and assess response in hepatic SOS. However, there are no pathognomonic findings that definitively distinguish SOS from other conditions in the differential diagnosis.</p><p>Findings that are more common in SOS than with other liver disorders in the post-transplant period include ascites, an abnormal portal vein waveform, marked thickening of the gallbladder wall, and a hepatic artery resistance index &gt;0.75 [<a href="#rid60">60</a>]. Reversal of blood flow in the portal vein by Doppler studies has been used to diagnose SOS, but the sensitivity is low [<a href="#rid61">61,62</a>]. One study prospectively determined the prevalence of sonographic hepatobiliary abnormalities in 21 patients undergoing HCT and reported abnormal baseline studies in 62 percent; serial examinations could not discriminate patients with SOS from those without the syndrome [<a href="#rid63">63</a>]. Measurement of liver stiffness by US is being studied, but test characteristics for SOS are not well defined [<a href="#rid64">64-66</a>].</p><p>Computed tomography or magnetic resonance angiography may be abnormal in patients with hepatic SOS, but they, too, lack specificity; descriptions of their use are primarily based on case reports [<a href="#rid67">67-69</a>].</p><p class="headingAnchor" id="H596139438"><span class="h2">Liver biopsy</span><span class="headingEndMark"> — </span>Liver biopsy and/or measurement of the portal-hepatic venous gradient can be used as diagnostic criteria for hepatic SOS, but there are substantial procedure-related risks. (See <a class="local">'EBMT diagnostic criteria for adults'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transjugular procedure </strong>– A transjugular approach (ie, accessing the venous system through the jugular vein) for liver biopsy is safer than a percutaneous biopsy. The transjugular biopsy procedure should be coupled with measurement of the portal-hepatic venous gradient. However, a study that included 60 patients with liver dysfunction who underwent transjugular liver biopsy and measurement of hepatic venous pressure reported bleeding complications in 18 percent, including three procedure-related deaths [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurement of the portal-hepatic venous gradient</strong> – Measurement of hepatic venous pressures compares the difference between the wedged hepatic venous pressure (which approximates the sinusoidal and portal pressures) and the free hepatic venous pressure. In one study, a hepatic venous pressure gradient &gt;10 mm Hg correlated with the presence of SOS, with 91 percent specificity and 86 percent positive predictive value [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic findings</strong> – Liver sinusoids may be dilated and congested by erythrocytes and nonthrombotic fibrous occlusion of the central veins and small venules; in severe cases, there is widespread zonal liver disruption and centrilobular hemorrhagic necrosis (<a class="graphic graphic_picture graphicRef63245" href="/d/graphic/63245.html" rel="external">picture 1</a>) [<a href="#rid71">71-75</a>]. Later pathologic changes include deposition of collagen in the sinusoids, sclerosis of venular walls, fibrosis of venular lumens, and occlusion of terminal hepatic venules and intercalated veins (<a class="graphic graphic_picture graphicRef76089" href="/d/graphic/76089.html" rel="external">picture 2</a>). </p><p></p><p class="headingAnchor" id="H1606606646"><span class="h1">DIAGNOSIS/DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of hepatic SOS should be considered in any patient who has undergone hematopoietic cell transplantation (HCT) and develops SOS-related symptoms, such as thrombocytopenia refractory to platelet transfusion, hepatomegaly, abdominal pain, ascites, fluid overload, and/or weight gain. There should be a high index of suspicion for this condition, as there is no pathognomonic biomarker, imaging characteristic, or biopsy feature and the presentation varies between individuals. </p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic SOS should be diagnosed using the European Society for Blood and Marrow Transplantation (EBMT) revised diagnostic criteria for adults [<a href="#rid75">75</a>] rather than alternative models (eg, Seattle, Baltimore), because the EBMT model is more sensitive and enables earlier detection compared with the other instruments. </p><p></p><p class="bulletIndent1">Compared with the Seattle or Baltimore instruments, the EBMT model increases the rate of detection of hepatic SOS and enables earlier diagnosis because it captures anicteric cases, those diagnosed after day 21, and includes alternative modes of diagnosis (eg, ultrasound, liver biopsy). No studies have directly compared the performance of the EBMT versus the Seattle or Baltimore models for adults. However, the Seattle and Baltimore models were compared in a meta-analysis that included nearly 25,000 HCT recipients from 135 studies; the incidence of SOS was 17 percent using the Seattle criteria, but only 10 percent using the more stringent Baltimore criteria [<a href="#rid1">1</a>]. In another retrospective study, 23 percent of 803 patients with SOS (using either the Baltimore criteria, Seattle criteria, or biopsy) had serum bilirubin &lt;2 mg/dL at the time of diagnosis; patients with an anicteric presentation (49 adults and 132 children) would not have been diagnosed using the Baltimore criteria alone [<a href="#rid76">76</a>]. A retrospective registry study reported that among 70 patients who were diagnosed with hepatic SOS according to EBMT criteria, only 24 were diagnosed based on the modified Seattle criteria and 11 met the Baltimore criteria [<a href="#rid77">77</a>].</p><p></p><p>Our approach to diagnosis and management of hepatic SOS in adults is consistent with recommendations of EBMT and GITMO (Gruppo Italiano Trapianto Midollo Osseo e Terapia Cellulare) [<a href="#rid75">75,78</a>].</p><p class="headingAnchor" id="H1020581672"><span class="h2">EBMT diagnostic criteria for adults</span><span class="headingEndMark"> — </span>Following are the revised EBMT diagnostic criteria for adults; note that these criteria accommodate both classical SOS (ie, &lt;21 days from HCT) and late-onset SOS (ie, ≥21 days after transplantation) [<a href="#rid75">75</a>].</p><p><strong>Classical SOS</strong> – Diagnosis requires [<a href="#rid75">75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bilirubin (≥2 mg/dL; ≥34 micromol/L) </p><p></p><p class="bulletIndent1"><strong>plus</strong> two of the following:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Painful hepatomegaly </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain &gt;5 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ascites</p><p></p><p><strong>Late-onset SOS</strong> – Diagnosis of late-onset SOS (ie, ≥21 days after transplantation) requires [<a href="#rid75">75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Classical SOS beyond day 21</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologically-proven SOS</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bilirubin ≥2 mg/dL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Painful hepatomegaly </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight gain &gt;5 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ascites</p><p></p><p class="bulletIndent2"><strong>plus </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic or ultrasound evidence of SOS</p><p></p><p class="headingAnchor" id="H3390824265"><span class="h2">Other diagnostic models</span><span class="headingEndMark"> — </span>As discussed above, we suggest use of the revised EBMT criteria for adults, rather than the following models, which are described for purposes of comparison. (See <a class="local">'Diagnosis/Differential diagnosis'</a> above.)</p><p class="headingAnchor" id="H1690261251"><span class="h3">Seattle</span><span class="headingEndMark"> — </span>The modified Seattle criteria define hepatic SOS by the otherwise-unexplained occurrence of ≥2 of the following findings within 20 days of HCT; the original Seattle model differed because it used weight gain &gt;2 percent as a criterion [<a href="#rid71">71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum bilirubin &gt;2 mg/dL </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly or right upper quadrant pain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sudden weight gain &gt;5 percent of baseline body weight</p><p></p><p class="headingAnchor" id="H3684220025"><span class="h3">Baltimore</span><span class="headingEndMark"> — </span>The Baltimore criteria define hepatic SOS based on [<a href="#rid79">79</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bilirubin &gt;2 mg/dL within 21 days of HCT </p><p></p><p class="bulletIndent1"><strong>plus</strong> at least two of the following: </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ascites</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain &gt;5 percent of baseline body weight</p><p></p><p class="headingAnchor" id="H556591706"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of SOS includes other causes of liver dysfunction, refractory thrombocytopenia, fluid overload, or multiorgan failure in patients who recently underwent HCT. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Engraftment syndrome/Capillary leak syndrome/Peri-engraftment respiratory distress syndrome (PERDS) </strong>– These<strong> </strong>syndromes generally occur 9 to 16 days after HCT and are thought to be related to release of proinflammatory cytokines during the period of neutrophil recovery. Each of these conditions can manifest ascites, edema, and weight gain that can resemble hepatic SOS; respiratory distress is a prominent feature of PERDS, which can resemble advanced stage SOS. These syndromes differ from SOS in that they generally manifest noninfectious fever and/or maculopapular rash, while abdominal pain, hepatomegaly, and liver dysfunction are less prominent features. (See  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute graft-versus-host disease</strong> <strong>(aGVHD) </strong>– Both SOS and aGVHD can present with abdominal pain and a rising serum bilirubin, but patients with aGVHD usually have concurrent rash and involvement of the gastrointestinal tract. The timing of aGVHD is generally later and coincides with engraftment, but this can overlap the timing of SOS, especially late presentations of SOS. Skin biopsy can distinguish these processes, but liver biopsy should not be performed in children because of excessive bleeding risk. (See  <a class="medical medical_review" href="/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal liver function </strong>– Numerous conditions cause abnormal liver function tests in the post-transplant period (<a class="graphic graphic_table graphicRef57570" href="/d/graphic/57570.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef71068" href="/d/graphic/71068.html" rel="external">table 3</a>). SOS may also share features of other causes of fulminant hepatic failure including ischemic, viral, malignant/infiltrative, and toxic hepatitis. Some of the most pertinent entities include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatic infections</strong> – Abnormal liver function tests may be due to viral hepatidities (eg, hepatitis B, hepatitis C), other viruses (eg, cytomegalovirus [CMV], varicella zoster [VZV], Epstein-Barr [EBV], human herpesvirus 6 [HHV-6], adenovirus), and hepatosplenic candidiasis; the likely causes vary with the timing after transplantation. A substantial rise of the transaminases is a hallmark of most such liver infections; in contrast, SOS is typically marked by early refractory thrombocytopenia, followed by a later rise in transaminases or bilirubin. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a>.)  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug toxicity</strong> – Many drugs used in the HCT setting, including calcineurin inhibitors (<a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>), <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, azole antifungal agents, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a>, and <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> are associated with cholestasis, but they primarily cause hepatocytic damage with elevated transaminases and are not associated with refractory thrombocytopenia that is seen in SOS. (See  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Budd-Chiari syndrome </strong>– The acute form of Budd-Chiari syndrome (BCS) can occasionally resemble hepatic SOS. BCS is caused by obstruction of hepatic veins and inferior vena cava, which can be established noninvasively by ultrasonography with Doppler studies, computed tomography scan, or magnetic resonance angiography. (See  <a class="medical medical_review" href="/d/html/3562.html" rel="external">"Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.) </p><p></p><p class="headingAnchor" id="H1052428602"><span class="h1">DISEASE SEVERITY</span><span class="headingEndMark"> — </span>Grading of hepatic SOS in adults (≥18 years) is based on the revised European Society for Blood and Marrow Transplantation (EBMT) criteria for SOS for adults, which incorporates the time since the first clinical symptoms, bilirubin level and kinetics, transaminases, weight gain, and renal function [<a href="#rid75">75</a>]. We use a simplified version of that score:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe/very severe</strong> – Severe/very severe hepatic SOS is characterized by multi-organ dysfunction or ≥2 of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Time from emergence of first clinical symptoms to diagnosis ≤4 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bilirubin: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>≥5 mg/dL (≥85 micromol/L)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Doubling &lt;48 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transaminases &gt;5 times upper limit of normal</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight gain &gt;5 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal function ≥1.5 times baseline at transplant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild/moderate</strong> – Mild or moderate hepatic SOS meets &lt;2 of the above criteria. Moderate disease should be upgraded to severe disease if the patient has ≥2 risk factors [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H567234867"><span class="h1">PROPHYLAXIS AND PREVENTION</span><span class="headingEndMark"> — </span>To reduce the incidence and severity of hepatic SOS and lessen morbidity and mortality, it is important to:</p><p class="bulletIndent1"><span class="glyph">●</span>Mitigate modifiable risk factors, when possible </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide prophylaxis </p><p></p><p class="headingAnchor" id="H620894823"><span class="h2">Modifiable risk factors</span><span class="headingEndMark"> — </span>Risk factors for hepatic SOS should be evaluated prior to hematopoietic cell transplantation (HCT). (See <a class="local">'Risk factors'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-existent liver disease/injury</strong> should be optimized prior to HCT:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medications, supplements, and other substances associated with liver injury should be avoided in the peritransplant period. Examples include azole antifungals, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, certain herbal remedies, and excessive alcohol consumption. (See  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury"</a> and  <a class="medical medical_review" href="/d/html/3618.html" rel="external">"Hepatotoxicity due to herbal medications and dietary supplements"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis C virus should be treated prior to HCT, if possible. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When possible, we avoid acute fluid overload in patients undergoing HCT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aggressive iron chelation may reduce the risk for SOS for patients with liver dysfunction caused by iron overload. (See  <a class="medical medical_review" href="/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretransplant/bridging therapy</strong> – If possible, we avoid treatment with <a class="drug drug_general" data-topicid="8968" href="/d/drug information/8968.html" rel="external">gemtuzumab ozogamicin</a> or <a class="drug drug_general" data-topicid="114511" href="/d/drug information/114511.html" rel="external">inotuzumab ozogamicin</a> immediately prior to transplantation because they are associated with a substantially increased risk for hepatic SOS. Alternative bridging treatments should be used, when possible. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspects of transplantation</strong> – A decision to modify aspects of transplantation to reduce the risk of SOS must be made in the context of management of the underlying disease, comorbid conditions, and institutional approach [<a href="#rid80">80,81</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Conditioning regimen</strong> – The conditioning regimen contributes importantly to the risk for hepatic SOS, and the following considerations may reduce risk:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Use of nonmyeloablative conditioning/reduced intensity conditioning, instead of myeloablative conditioning.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Avoidance of busulfan-based conditioning and total body irradiation (TBI)-containing regimens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Graft source</strong> – Allogeneic grafts are associated with greater risk than autologous grafts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft-versus-host disease (GVHD) prophylaxis</strong> – When possible, avoidance of higher-risk GVHD prophylaxis regimens, such as: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> plus <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> plus <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> plus <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a></p><p></p><p class="bulletIndent1">Some experts also avoid cyclosporine-containing regimens.</p><p></p><p class="headingAnchor" id="H997928159"><span class="h2">Prophylaxis</span><span class="headingEndMark"> — </span>We provide prophylaxis to all adults undergoing HCT, but some institutions limit prophylaxis to various high-risk patient groups. (See <a class="local">'Risk factors'</a> above.)</p><p>For adults undergoing HCT, we suggest prophylaxis with <a class="drug drug_general" data-topicid="10033" href="/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> (UDCA) rather than no prophylaxis or prophylaxis using <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> or other agents, based on a meta-analysis of four randomized controlled trials that reported reduced incidence of SOS, decreased mortality attributable to SOS, no impact on overall survival (OS), but no increase in adverse effects with UDCA [<a href="#rid82">82</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UDCA</strong> – UDCA is a naturally-occurring hydrophilic bile acid that decreases hepatotoxicity by reducing the hydrophobicity of other naturally-occurring bile acids; UDCA may also decrease secretion of proinflammatory cytokines, thereby minimizing the injury to hepatic sinusoidal endothelial cells [<a href="#rid3">3,54,83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and toxicity</strong> – We administer UDCA (total daily dose 12 mg/kg or 600 mg orally, divided in two doses) beginning the day before the preparative regimen begins (ie, day –1) and continue treatment for three months. If mucositis or nausea interrupts administration of UDCA, we resume treatment when the patient is again able to take oral medications. UDCA is well-tolerated; the major adverse effects are rash and diarrhea in &lt;5 percent of cases. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong>– UDCA prophylaxis is associated with a reduced incidence of hepatic SOS and SOS-associated mortality, but there is no clear impact on OS. A Cochrane analysis that included four trials (612 participants) compared UDCA (alone, or with another agent) versus placebo, no treatment, or the same additional agent [<a href="#rid82">82</a>]. Based on low or very low quality of evidence, the analysis reported that UDCA prophylaxis is associated with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced incidence of hepatic SOS (risk ratio [RR] 0.60; 95% CI 0.40-0.88) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased mortality due to hepatic SOS (RR 0.27, 95% CI 0.09-0.87)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible reduction in all-cause mortality (RR 0.70, 95% CI 0.50-0.99)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No effect on OS (hazard ratio [HR] 0.83, 95% CI 0.59-1.18)</p><p></p><p>The Cochrane analysis also reported that there was no proven benefit for prophylaxis using other agents (eg, heparin, antithrombin III, PGE1, <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">pentoxifylline</a>) and some are associated with substantial adverse effects (eg, hemorrhage) [<a href="#rid82">82</a>]. Another meta-analysis and systematic review that included 2782 patients enrolled on 12 studies of prophylactic low molecular weight heparin or <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> found no reduction in risk of SOS [<a href="#rid84">84</a>].</p><p>Prophylaxis with UDCA is recommended by the European Society for Blood and Marrow Transplantation Handbook and the British Committee for Standards in Haematology/British Society for Blood and Marrow Transplantation guidelines [<a href="#rid81">81</a>]. </p><p class="headingAnchor" id="H3418193699"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>It is important to have a high index of suspicion for the diagnosis of hepatic SOS and to initiate treatment promptly. Waiting to satisfy all diagnostic criteria will delay the initiation of therapy and increase the risk of progressive organ dysfunction and death. Diagnostic criteria for adults are described above. (See <a class="local">'EBMT diagnostic criteria for adults'</a> above.)</p><p>Treatment is influenced by disease severity, which is assessed as described above. (See <a class="local">'Disease severity'</a> above.)</p><p class="headingAnchor" id="H3668734876"><span class="h2">Mild/moderate SOS</span><span class="headingEndMark"> — </span>Patients with mild or moderate severity SOS generally do well with supportive care measures alone, but they must be monitored for progression to severe disease. <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">Defibrotide</a> or other treatments are not well-studied for patients with mild or moderate SOS.</p><p>The following supportive measures should be implemented:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain euvolemia – Daily weights and recording of fluid intake and output are critical to maintaining euvolemia, which is important for adequate renal perfusion, while avoiding restricted pulmonary function due to ascites. Weight gain per se is not a major concern if it does not compromise pulmonary function. Fluid restriction and diuresis should be initiated when intake exceeds output, but it is important to avoid overly aggressive fluid management that can lead to a prerenal failure due to third spacing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minimize hepatotoxic agents – Patients should avoid medications associated with hepatotoxic side effects, including nonsteroidal anti-inflammatory drugs. Pain control may require narcotics to avoid excessive use of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paracentesis – Patients may require serial paracenteses or continuous drainage for ascites that causes discomfort or pulmonary compromise. The amount of fluid removed at each session should be limited to maintain renal perfusion.</p><p></p><p>For patients who do not improve with supportive care or who develop progressive disease, we treat for severe SOS, as described above. (See <a class="local">'Severe SOS'</a> below.)</p><p class="headingAnchor" id="H2395155434"><span class="h2">Severe SOS</span><span class="headingEndMark"> — </span>For patients with severe/very severe hepatic SOS, we suggest prompt treatment with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a>, rather than supportive care alone or other treatments. Defibrotide treatment for severe SOS was associated with improved survival, according to a multicenter study of defibrotide treatment versus matched historical control patients [<a href="#rid85">85</a>] and a systematic review of 17 studies [<a href="#rid86">86</a>]. No randomized controlled trials have compared defibrotide with other treatments, but heparin, tissue plasminogen activator, antithrombin III, glucocorticoids, and prostaglandin E1 have no proven efficacy and/or are associated with severe adverse effects (eg, hemorrhage) [<a href="#rid8">8,87-91</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defibrotide</strong> – <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">Defibrotide</a> is a sodium salt of single-stranded oligodeoxyribonucleotides derived from DNA of porcine intestinal mucosa [<a href="#rid92">92</a>]. Its mechanism of action is not well-understood, but it may involve endothelial protection, restoration of thrombo-fibrinolytic balance, and/or anti-inflammatory properties [<a href="#rid93">93,94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">Defibrotide</a> is administered 6.25 mg/kg every 6 hours intravenously for ≥21 days, until SOS resolution or hospital discharge, up to a maximum of 60 days [<a href="#rid85">85</a>]. Defibrotide should be discontinued ≥2 hours prior to invasive procedures and can be resumed once any procedure-related risk of bleeding is resolved. There is no known reversal agent, but the half-life of elimination is &lt;2 hours.</p><p></p><p class="bulletIndent1">For patients who develop severe SOS while receiving <a class="drug drug_general" data-topicid="10033" href="/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> (UDCA) prophylaxis, we generally continue UDCA while treating with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a>.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">Defibrotide</a> is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treatment of severe hepatic SOS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">Defibrotide</a> should be started promptly for severe SOS, as early initiation of treatment is associated with improved overall survival (OS) [<a href="#rid95">95,96</a>]. Most studies treated with defibrotide for 14 to 21 days, but the optimal duration of treatment has not been formally defined. In a pooled analysis, more than half of patients who achieved a complete response (CR) required &gt;3 weeks of persistent treatment with defibrotide to achieve CR [<a href="#rid97">97</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse effects of <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> are hypotension, diarrhea, nausea, vomiting, and epistaxis. Hemorrhage and hypersensitivity reactions are reported in &lt;2 percent of patients but can be life-threatening; defibrotide should be discontinued permanently in patients with a severe or life-threatening hypersensitivity reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Treatment with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> is associated with improved survival in patients with severe/very severe hepatic SOS, compared with supportive care alone. Historically, mortality with severe hepatic SOS was &gt;80 percent [<a href="#rid1">1,98,99</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A multicenter study of children and adults reported that, compared with 32 historical control patients, 39 patients treated with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> had superior day +100 OS (38 versus 25 percent, respectively) and day +100 CR (26 versus 13 percent) [<a href="#rid85">85</a>]. Treatment was well-tolerated with manageable toxicity; fatal hemorrhagic events were reported in 15 percent of defibrotide-treated patients, compared with 6 percent of controls.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic analysis of <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> treatment included 17 studies (2598 patients) and reported day +100 OS was 54 percent (range 35 to 79 percent) [<a href="#rid86">86</a>]. Other studies of defibrotide for SOS reported similar outcomes and toxicity [<a href="#rid95">95,100</a>].</p><p></p><p class="bulletIndent1">There are no reports of recurrent SOS in patients who achieve a CR with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a>, and most patients who recover from SOS regain normal liver function and do not develop portal hypertension or esophageal varices.</p><p></p><p class="headingAnchor" id="H797875903"><span class="h2">Response to treatment</span><span class="headingEndMark"> — </span>Clinical findings, laboratory studies, and abdominal ultrasound are used to evaluate the response to treatment, as described above. (See <a class="local">'Evaluation'</a> above.)</p><p>A CR should include improved platelet count and response to platelet transfusions, resolution of coagulopathy, effective diuresis and weight loss, resolution of third spacing of fluids, and resolution of hyperbilirubinemia and hepatomegaly [<a href="#rid97">97</a>]. </p><p>For patients who do not improve with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> treatment for ≥21 days, we consider treatment for refractory disease, as described below. (See <a class="local">'Refractory disease'</a> below.)</p><p class="headingAnchor" id="H3005533902"><span class="h1">REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>No pharmacologic agent has proven benefit for patients with severe hepatic SOS who do not respond adequately to ≥3 weeks of <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> treatment. Descriptions of treatment for refractory disease are primarily small, uncontrolled series or case reports. </p><p>Options for management of refractory disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>High dose <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> may be considered for treatment of SOS, but it should be used with caution due to the high risk of infection [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insertion of a transjugular intrahepatic portosystemic stent-shunt (TIPS) has been performed in small numbers of patients with SOS; some had regression of hepatic and renal symptoms [<a href="#rid101">101-103</a>]. Patients with milder disease are more likely to respond; long-term survival is uncommon but has been reported [<a href="#rid103">103-105</a>]. (See  <a class="medical medical_review" href="/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orthotopic liver transplantation has been successfully performed in small numbers of patients with SOS [<a href="#rid106">106,107</a>]. However, the most patients with severe SOS are not medically fit enough to undergo such a rigorous surgical procedure. In addition, patients at risk for recurrent malignancy are low-priority candidates for liver transplant at many centers. (See  <a class="medical medical_review" href="/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.) </p><p></p><p class="headingAnchor" id="H1817220223"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease (VOD), is a life-threatening complication that develops in up to 15 percent of adults who undergo hematopoietic cell transplantation (HCT). A high index of suspicion is required to make the diagnosis, and prompt treatment is needed to reduce the substantial morbidity and mortality associated with SOS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Risk factors for hepatic SOS after HCT include pretransplant patient characteristics (eg, liver disease, age, underlying disease) and transplantation-related factors (eg, conditioning regimen, graft source, graft-versus-host disease [GVHD] prophylaxis regimen) (<a class="graphic graphic_table graphicRef91604" href="/d/graphic/91604.html" rel="external">table 1</a>). Rarely, hepatic SOS can be caused by therapeutic immunoconjugates, radiation therapy, or solid organ transplantation. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Most patients present within 21 days of HCT with an increased need for platelet transfusions, weight gain, ascites, jaundice, and/or firm, tender hepatomegaly. However, presentations vary and patients may present &gt;21 days after transplantation or without jaundice. Dyspnea, tachypnea, or other evidence of fluid overload may accompany renal, cardiac, or pulmonary dysfunction in patients who progress to multiorgan failure. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Evaluation of suspected SOS is primarily based on clinical and laboratory findings; abdominal ultrasound and liver biopsy are important, but not essential, aspects of evaluation and diagnosis. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> <strong>and differential diagnosis</strong> – The diagnosis of SOS should be considered in any patient who has undergone HCT and develops refractory thrombocytopenia, fluid overload, hepatomegaly, abdominal pain, weight gain, and/or ascites. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – Hepatic SOS should be diagnosed using the European Society for Blood and Marrow Transplantation (EBMT) revised diagnostic criteria for adults [<a href="#rid75">75</a>], rather than alternative models (eg, Seattle, Baltimore), because it is more sensitive and enables earlier detection compared with the other instruments. EBMT criteria for the diagnosis of classical and late-onset hepatic SOS in adults are presented above. (See <a class="local">'Diagnosis/Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Differential diagnosis</strong> – The differential diagnosis of SOS includes other causes of liver dysfunction, refractory thrombocytopenia, fluid overload, or multiorgan failure in patients who recently underwent HCT, including engraftment syndrome, capillary leak syndrome, peri-engraftment respiratory distress syndrome (PERDS), acute GVHD, and other infectious and chemical causes of liver dysfunction. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis and prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Modify risk factors</strong> – Risk factors for hepatic SOS should be evaluated prior to HCT, with consideration for modification, when possible. (See <a class="local">'Modifiable risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylaxis</strong> – We provide prophylaxis for adults who have at least one major risk factor for hepatic SOS, as described above. Some institutions favor prophylaxis for all adults undergoing HCT. (See <a class="local">'Prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2">For prophylaxis against SOS in adults, we suggest <a class="drug drug_general" data-topicid="10033" href="/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> (UDCA) rather than no treatment or prophylaxis with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a> or other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), based on reduced incidence of SOS, decreased mortality attributable to SOS, no increase in adverse effects, but no impact on overall survival [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – We treat SOS according to the severity of disease, determined according to EBMT criteria, as described above (see <a class="local">'Disease severity'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild/moderate</strong> – Patients with mild or moderate severity SOS generally do well with supportive care measures, including maintaining euvolemia, avoiding hepatotoxic agents, and paracentesis as needed to relieve abdominal pain. Patients should be monitored for progression to severe/very severe disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe/very severe</strong> – For patients with severe or very severe hepatic SOS, we suggest treatment with <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a>, rather than supportive care alone or other approaches (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>), based on improved survival in a meta-analysis and prospective studies [<a href="#rid85">85,86,95,100</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong> – There is no well-defined treatment for severe SOS that does not respond to <a class="drug drug_general" data-topicid="83451" href="/d/drug information/83451.html" rel="external">defibrotide</a>, but high-dose glucocorticoids, transjugular intrahepatic portosystemic stent-shunt (TIPS), and liver transplantation have been used in selected cases. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16:157.</a></li><li><a class="nounderline abstract_t">Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92:3599.</a></li><li><a class="nounderline abstract_t">Carreras E, Díaz-Beyá M, Rosiñol L, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011; 17:1713.</a></li><li><a class="nounderline abstract_t">Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015; 50:781.</a></li><li><a class="nounderline abstract_t">Yakushijin K, Atsuta Y, Doki N, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transplant 2016; 51:403.</a></li><li><a class="nounderline abstract_t">Dalle JH, Giralt SA. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Biol Blood Marrow Transplant 2016; 22:400.</a></li><li><a class="nounderline abstract_t">McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255.</a></li><li><a class="nounderline abstract_t">Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90:1396.</a></li><li><a class="nounderline abstract_t">El-Sayed MH, El-Haddad A, Fahmy OA, et al. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation. Eur J Gastroenterol Hepatol 2004; 16:1347.</a></li><li><a class="nounderline abstract_t">Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17:225.</a></li><li><a class="nounderline abstract_t">Dulley FL, Kanfer EJ, Appelbaum FR, et al. Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987; 43:870.</a></li><li><a class="nounderline abstract_t">Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85:3005.</a></li><li><a class="nounderline abstract_t">Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114:1270.</a></li><li><a class="nounderline abstract_t">Lee SH, Yoo KH, Sung KW, et al. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transplant 2010; 45:1287.</a></li><li><a class="nounderline abstract_t">Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991; 77:195.</a></li><li><a class="nounderline abstract_t">Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83:1998.</a></li><li><a class="nounderline abstract_t">Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29:1893.</a></li><li><a class="nounderline abstract_t">Rodriguez-Iñigo E, Tomás JF, Gómez-García de Soria V, et al. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study. Blood 1997; 90:1326.</a></li><li><a class="nounderline abstract_t">Locasciulli A, Bacigalupo A, VanLint MT, et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16:407.</a></li><li><a class="nounderline abstract_t">Norol F, Roche B, Girardin MF, et al. Hepatitis C virus infection and allogeneic bone marrow transplantation. Transplantation 1994; 57:393.</a></li><li><a class="nounderline abstract_t">Matute-Bello G, McDonald GD, Hinds MS, et al. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21:1125.</a></li><li><a class="nounderline abstract_t">Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40:935.</a></li><li><a class="nounderline abstract_t">Maximova N, Ferrara G, Minute M, et al. Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant. Int J Hematol 2014; 99:766.</a></li><li><a class="nounderline abstract_t">Marsh JC. Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Hepatology 1989; 9:790.</a></li><li><a class="nounderline abstract_t">Morgan M, Dodds A, Atkinson K, et al. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77:529.</a></li><li><a class="nounderline abstract_t">Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84:321.</a></li><li><a class="nounderline abstract_t">Wall DA, Chan KW, Nieder ML, et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010; 54:291.</a></li><li><a class="nounderline abstract_t">Takahashi M, Harada S, Suzuki H, et al. Regorafenib could cause sinusoidal obstruction syndrome. J Gastrointest Oncol 2016; 7:E41.</a></li><li><a class="nounderline abstract_t">Choi JH, Won YW, Kim HS, et al. Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver. Oncol Lett 2016; 11:2861.</a></li><li><a class="nounderline abstract_t">Magwood-Golston JS, Kessler S, Bennett CL. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res 2016; 44:61.</a></li><li><a class="nounderline abstract_t">Vassal G, Hartmann O, Benhamou E. Busulfan and veno-occlusive disease of the liver. Ann Intern Med 1990; 112:881.</a></li><li><a class="nounderline abstract_t">McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101:2043.</a></li><li><a class="nounderline abstract_t">de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 94:1226.</a></li><li><a class="nounderline abstract_t">Faraci M, Bertaina A, Luksch R, et al. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. Biol Blood Marrow Transplant 2019; 25:313.</a></li><li><a class="nounderline abstract_t">Strouse C, Zhang Y, Zhang MJ, et al. Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant 2018; 24:2072.</a></li><li><a class="nounderline abstract_t">Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76:1867.</a></li><li><a class="nounderline abstract_t">Deeg HJ, Sullivan KM, Buckner CD, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant 1986; 1:151.</a></li><li><a class="nounderline abstract_t">Girinsky T, Benhamou E, Bourhis JH, et al. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 2000; 18:981.</a></li><li><a class="nounderline abstract_t">Soiffer RJ, Dear K, Rabinowe SN, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991; 52:1014.</a></li><li><a class="nounderline abstract_t">Moscardó F, Urbano-Ispizua A, Sanz GF, et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31:545.</a></li><li><a class="nounderline abstract_t">Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112:4425.</a></li><li><a class="nounderline abstract_t">Carmona A, Díaz-Ricart M, Palomo M, et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant 2013; 19:1439.</a></li><li><a class="nounderline abstract_t">Richardson P, Linden E, Revta C, Ho V. Use of defibrotide in the treatment and prevention of veno-occlusive disease. Expert Rev Hematol 2009; 2:365.</a></li><li><a class="nounderline abstract_t">McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31:599.</a></li><li><a class="nounderline abstract_t">Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102:1578.</a></li><li><a class="nounderline abstract_t">Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk 2013; 13:296.</a></li><li><a class="nounderline abstract_t">Richardson PG, Corbacioglu S. Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J 2020; 10:29.</a></li><li><a class="nounderline abstract_t">Brown AC. Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of 5 series. Food Chem Toxicol 2016.</a></li><li><a class="nounderline abstract_t">Willemart S, Nicaise N, Struyven J, van Gansbeke D. Acute radiation-induced hepatic injury: evaluation by triphasic contrast enhanced helical CT. Br J Radiol 2000; 73:544.</a></li><li><a class="nounderline abstract_t">Sempoux C, Horsmans Y, Geubel A, et al. Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 1997; 26:128.</a></li><li><a class="nounderline abstract_t">Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112:1538.</a></li><li><a class="nounderline abstract_t">Sebagh M, Debette M, Samuel D, et al. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 1999; 30:1144.</a></li><li><a class="nounderline abstract_t">Nakazawa Y, Chisuwa H, Mita A, et al. Life-threatening veno-occlusive disease after living-related liver transplantation. Transplantation 2003; 75:727.</a></li><li><a class="nounderline abstract_t">Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011; 46:1495.</a></li><li><a class="nounderline abstract_t">Zeniya M, Fukata H, Toda G. Thrombomodulin expression of sinusoidal endothelial cells in chronic viral hepatitis. J Gastroenterol Hepatol 1995; 10 Suppl 1:S77.</a></li><li><a class="nounderline abstract_t">Scoazec JY, Feldmann G. In situ immunophenotyping study of endothelial cells of the human hepatic sinusoid: results and functional implications. Hepatology 1991; 14:789.</a></li><li><a class="nounderline abstract_t">Volpes R, van den Oord JJ, Desmet VJ. Distribution of the VLA family of integrins in normal and pathological human liver tissue. Gastroenterology 1991; 101:200.</a></li><li><a class="nounderline abstract_t">Kernan NA, Grupp S, Smith AR, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol 2018; 181:816.</a></li><li><a class="nounderline abstract_t">Rio B, Andreu G, Nicod A, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67:1773.</a></li><li><a class="nounderline abstract_t">Sharafuddin MJ, Foshager MC, Steinbuch M, et al. Sonographic findings in bone marrow transplant patients with symptomatic hepatic venoocclusive disease. J Ultrasound Med 1997; 16:575.</a></li><li><a class="nounderline abstract_t">Herbetko J, Grigg AP, Buckley AR, Phillips GL. Venoocclusive liver disease after bone marrow transplantation: findings at duplex sonography. AJR Am J Roentgenol 1992; 158:1001.</a></li><li><a class="nounderline abstract_t">Teefey SA, Brink JA, Borson RA, Middleton WD. Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: value of duplex sonography. AJR Am J Roentgenol 1995; 164:1397.</a></li><li><a class="nounderline abstract_t">Hommeyer SC, Teefey SA, Jacobson AF, et al. Venocclusive disease of the liver: prospective study of US evaluation. Radiology 1992; 184:683.</a></li><li><a class="nounderline abstract_t">Dietrich CF, Trenker C, Fontanilla T, et al. New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome. Ultrasound Med Biol 2018; 44:2171.</a></li><li><a class="nounderline abstract_t">Colecchia A, Ravaioli F, Sessa M, et al. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. Biol Blood Marrow Transplant 2019; 25:995.</a></li><li><a class="nounderline abstract_t">Zama D, Bossù G, Ravaioli F, et al. Longitudinal evaluation of liver stiffness in three pediatric patients with veno-occlusive disease. Pediatr Transplant 2019; 23:e13456.</a></li><li><a class="nounderline abstract_t">van den Bosch MA, van Hoe L. MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation. Eur Radiol 2000; 10:1290.</a></li><li><a class="nounderline abstract_t">Dumont Ch, Lambert M, Van Beers BE. MR imaging findings in a patient with hepatic veno-occlusive disease. Acta Gastroenterol Belg 2004; 67:236.</a></li><li><a class="nounderline abstract_t">Yang DM, Jung DH, Park CH, et al. Imaging findings of hepatic sinusoidal dilatation. AJR Am J Roentgenol 2004; 183:1075.</a></li><li><a class="nounderline abstract_t">Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59:1015.</a></li><li><a class="nounderline abstract_t">McDonald GB, Sharma P, Matthews DE, et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4:116.</a></li><li><a class="nounderline abstract_t">Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127:549.</a></li><li><a class="nounderline abstract_t">Shulman HM, Fisher LB, Schoch HG, et al. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19:1171.</a></li><li><a class="nounderline abstract_t">Ruggiu M, Bedossa P, Rautou PE, et al. Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. Biol Blood Marrow Transplant 2018; 24:2523.</a></li><li><a class="nounderline abstract_t">Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016; 51:906.</a></li><li><a class="nounderline abstract_t">Corbacioglu S, Kernan NA, Pagliuca A, et al. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. Biol Blood Marrow Transplant 2020; 26:1342.</a></li><li><a class="nounderline abstract_t">Bazarbachi AH, Al Hamed R, Labopin M, et al. Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant 2021; 56:917.</a></li><li><a class="nounderline abstract_t">Bonifazi F, Sica S, Angeletti A, et al. Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group. Transplantation 2021; 105:686.</a></li><li><a class="nounderline abstract_t">Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44:778.</a></li><li><a class="nounderline abstract_t">Corbacioglu S, Jabbour EJ, Mohty M. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant 2019; 25:1271.</a></li><li><a class="nounderline abstract_t">Dignan FL, Wynn RF, Hadzic N, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013; 163:444.</a></li><li><a class="nounderline abstract_t">Cheuk DK, Chiang AK, Ha SY, Chan GC. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2015; :CD009311.</a></li><li><a class="nounderline abstract_t">Fusté B, Mazzara R, Escolar G, et al. Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK. Haematologica 2004; 89:578.</a></li><li><a class="nounderline abstract_t">Imran H, Tleyjeh IM, Zirakzadeh A, et al. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant 2006; 37:677.</a></li><li><a class="nounderline abstract_t">Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 2016; 127:1656.</a></li><li><a class="nounderline abstract_t">Richardson P, Aggarwal S, Topaloglu O, et al. Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplant 2019; 54:1951.</a></li><li><a class="nounderline abstract_t">Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006; 91:795.</a></li><li><a class="nounderline abstract_t">Bearman SI, Lee JL, Barón AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89:1501.</a></li><li><a class="nounderline abstract_t">Bajwa RP, Cant AJ, Abinun M, et al. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant 2003; 31:591.</a></li><li><a class="nounderline abstract_t">Al Beihany A, Al Omar H, Sahovic E, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant 2008; 41:287.</a></li><li><a class="nounderline abstract_t">Schlegel PG, Haber HP, Beck J, et al. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin. Ann Hematol 1998; 76:37.</a></li><li><a class="nounderline abstract_t">Kornblum N, Ayyanar K, Benimetskaya L, et al. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides 2006; 16:105.</a></li><li><a class="nounderline abstract_t">Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of  defibrotide. Expert Opin Drug Saf 2013; 12:123.</a></li><li><a class="nounderline abstract_t">Pescador R, Capuzzi L, Mantovani M, et al. Defibrotide: properties and clinical use of an old/new drug. Vascul Pharmacol 2013; 59:1.</a></li><li><a class="nounderline abstract_t">Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33:189.</a></li><li><a class="nounderline abstract_t">Richardson PG, Smith AR, Triplett BM, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol 2017; 178:112.</a></li><li><a class="nounderline abstract_t">Corbacioglu S, Richardson PG. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. Expert Rev Gastroenterol Hepatol 2017; 11:885.</a></li><li><a class="nounderline abstract_t">Sakai M, Strasser SI, Shulman HM, et al. Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome. Bone Marrow Transplant 2009; 44:441.</a></li><li><a class="nounderline abstract_t">Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol 2015; 168:481.</a></li><li><a class="nounderline abstract_t">Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92:737.</a></li><li><a class="nounderline abstract_t">Smith FO, Johnson MS, Scherer LR, et al. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996; 18:643.</a></li><li><a class="nounderline abstract_t">Lévy V, Azoulay D, Rio B, et al. Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS). Bone Marrow Transplant 1996; 18:443.</a></li><li><a class="nounderline abstract_t">Fried MW, Connaghan DG, Sharma S, et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24:588.</a></li><li><a class="nounderline abstract_t">Azoulay D, Castaing D, Lemoine A, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25:987.</a></li><li><a class="nounderline abstract_t">Annaloro C, Robbiolo L, Pozzoli E, et al. Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation. Leuk Lymphoma 2004; 45:1485.</a></li><li><a class="nounderline abstract_t">Hágglund H, Ringdén O, Ericzon BG, et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996; 62:1076.</a></li><li><a class="nounderline abstract_t">Rosen HR, Martin P, Schiller GJ, et al. Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver. Liver Transpl Surg 1996; 2:225.</a></li></ol></div><div id="topicVersionRevision">Topic 129806 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766729" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808553" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21708110" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25798682" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26595082" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26431626" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420443" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219577" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618844" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640171" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association of busulfan area under the curve with veno-occlusive disease following BMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3296355" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756636" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The syndrome of hepatic veno-occlusive disease after marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19401560" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010866" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984795" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7511444" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347135" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242569" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8535314" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509088" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hepatitis C virus infection and allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645575" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768390" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24715523" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2707742" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025579" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580502" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19743300" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27284487" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Regorafenib could cause sinusoidal obstruction syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27073565" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27030962" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2344115" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Busulfan and veno-occlusive disease of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406916" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622453" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266674" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29928989" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2224134" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3332129" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694547" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1750063" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829031" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18776081" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845694" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21082942" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of defibrotide in the treatment and prevention of veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16959316" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738663" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23313065" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32132522" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402097" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of 5 series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884753" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute radiation-induced hepatic injury: evaluation by triphasic contrast enhanced helical CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214461" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260156" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Liver disease induced by radioembolization of liver tumors: description and possible risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534334" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640317" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Life-threatening veno-occlusive disease after living-related liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460864" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The role of the endothelium in the short-term complications of hematopoietic SCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589350" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thrombomodulin expression of sinusoidal endothelial cells in chronic viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1937383" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : In situ immunophenotyping study of endothelial cells of the human hepatic sinusoid: results and functional implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2044908" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Distribution of the VLA family of integrins in normal and pathological human liver tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29767845" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3518836" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9321776" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sonographic findings in bone marrow transplant patients with symptomatic hepatic venoocclusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1566656" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Venoocclusive liver disease after bone marrow transplantation: findings at duplex sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7754881" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: value of duplex sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1509050" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Venocclusive disease of the liver: prospective study of US evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076031" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660772" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31081161" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Longitudinal evaluation of liver stiffness in three pediatric patients with veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10939493" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15285583" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : MR imaging findings in a patient with hepatic veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385307" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Imaging findings of hepatic sinusoidal dilatation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7709437" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6363247" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2438942" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175139" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30071321" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27183098" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32200121" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33208915" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33273315" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3321587" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Venoocclusive disease of the liver following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30797942" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24102514" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26017019" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136221" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16489362" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26825712" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30804485" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769582" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9057629" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692627" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17982501" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486923" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16584299" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23228043" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Drug safety evaluation of  defibrotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23680861" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Defibrotide: properties and clinical use of an old/new drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14661036" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28444784" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28825848" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19308033" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25401997" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9680339" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879632" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8864460" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781329" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10800068" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15359654" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8900305" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9346652" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
